Inopharma key facts
as of Oct 2026- Developer of hemostatic medical devices designed to control bleeding in emergency and clinical environments.
- Inopharma is valued at approximately $4.2M as of Oct 2026 (last reported valuation).
- It has raised $10K; the latest was Early Stage VC in Jun 2027.
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, A-One AC, Find Us, InfoBank — 9 tracked in total.
- Status: Privately Held (backing).
Inopharma's last reported valuation, Apr 2026. Nothing priced has surfaced since.
- ·Watch Inopharma: the Monday email on marks, rounds and moves
Inopharma funding rounds
No funding rounds for Inopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Inopharma valuation
Inopharma's last reported valuation was $4.2 million in Apr 2026. No priced round, secondary trade or fund mark has surfaced since.
Inopharma investors
9 investors are on record for Inopharma, including Tech Incubator Program for Startup, Center for Creative Economy and Innovation, A-One AC and Find Us.
About Inopharma
Developer of hemostatic medical devices designed to control bleeding in emergency and clinical environments. The company offers products such as hemostatic agents, soft tissue strengtheners, and anti-adhesion agents, enabling healthcare providers and users to rapidly stop bleeding in surgical, trauma, and first-aid situations.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2023
- Employees
- 7
- Website
- innophm.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.